ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide.
Share Price & News
How has ANGLE's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGL is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: AGL's weekly volatility (6%) has been stable over the past year.
7 Day Return
GB Medical Equipment
1 Year Return
GB Medical Equipment
Return vs Industry: AGL exceeded the UK Medical Equipment industry which returned 2.7% over the past year.
Return vs Market: AGL exceeded the UK Market which returned 22% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ANGLE's share price compared to the market and industry in the last 5 years?
Simply Wall St News
ANGLE Fundamentals Summary
|AGL fundamental statistics|
Is AGL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGL income statement (TTM)|
|Cost of Revenue||UK£674.00k|
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
Sep 30, 2021
|Earnings per share (EPS)||-0.065|
|Net Profit Margin||-1,523.10%|
How did AGL perform over the long term?See historical performance and comparison
Is ANGLE undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGL is unprofitable, so we can't compare its PE Ratio to the UK Medical Equipment industry average.
PE vs Market: AGL is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGL is overvalued based on its PB Ratio (8x) compared to the GB Medical Equipment industry average (3.6x).
How is ANGLE forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGL's revenue (56.2% per year) is forecast to grow faster than the UK market (5% per year).
High Growth Revenue: AGL's revenue (56.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AGL is forecast to be unprofitable in 3 years.
How has ANGLE performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGL is currently unprofitable.
Growing Profit Margin: AGL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGL is unprofitable, and losses have increased over the past 5 years at a rate of 16.7% per year.
Accelerating Growth: Unable to compare AGL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGL is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (97.5%).
Return on Equity
High ROE: AGL has a negative Return on Equity (-33.79%), as it is currently unprofitable.
How is ANGLE's financial position?
Financial Position Analysis
Short Term Liabilities: AGL's short term assets (£32.9M) exceed its short term liabilities (£3.8M).
Long Term Liabilities: AGL's short term assets (£32.9M) exceed its long term liabilities (£928.0K).
Debt to Equity History and Analysis
Debt Level: AGL is debt free.
Reducing Debt: AGL has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGL has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AGL has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 19.2% each year.
What is ANGLE current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGL's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Andrew David Newland (59 yo)
Mr. Andrew David William Newland, Meng, ACA founded ANGLE Plc in 1994 and serves as its Group Chief Executive. Mr. Newland founded Provexis, the first ever spin-out of Rowett Institute, Europe’s leading nu...
CEO Compensation Analysis
Compensation vs Market: Andrew David's total compensation ($USD534.86K) is about average for companies of similar size in the UK market ($USD739.80K).
Compensation vs Earnings: Andrew David's compensation has increased whilst the company is unprofitable.
Experienced Management: AGL's management team is considered experienced (3.8 years average tenure).
Experienced Board: AGL's board of directors are considered experienced (6.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.9%.
ANGLE plc's company bio, employee growth, exchange listings and data sources
- Name: ANGLE plc
- Ticker: AGL
- Exchange: AIM
- Founded: 1994
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: UK£274.640m
- Shares outstanding: 234.73m
- Website: https://angleplc.com
Number of Employees
- ANGLE plc
- Surrey Research Park
- 10 Nugent Road
- GU2 7AF
- United Kingdom
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products worldwide. The company develops and commercializes Parsortix cell separation system, which captures and harvests c...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/21 22:34|
|End of Day Share Price||2021/09/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.